Pharmacokinetics of favipiravir in adults with mild COVID-19 in Thailand
Manosuthi, W.; Prasanchaimontri, I.-o.; Niyomnaitham, S.; Sirijatuphat, R.; Charoenpong, L.; Copeland, K.; Cressey, T. R.; Mokmued, P.; Chokephaibulkit, K.
Show abstract
We assessed the pharmacokinetics of favipiravir (FPV) in adults with symptomatic SARS-CoV-2 infection without pneumonia in Thailand. FPV dosing was 1800 mg twice-daily on day 1, then 800 mg twice-daily for 14 days. Eight subjects (7 female), median (range) age 39 (19-53) years and BMI 27.9 (18.0-33.6) were included. Inter-subject variability was high but all achieved minimum plasma concentrations (Cmin) above EC50 (9.7 mg/L). FPV was well tolerated; 1 subject stopped prematurely due to rash.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Human Safety, Tolerability, and Pharmacokinetics of a Novel Broad-Spectrum Oral Antiviral Compound, Molnupiravir, with Activity Against SARS-CoV-2 96%
- Pharmacokinetics and safety of XAV-19, a swine glyco-humanized polyclonal anti-SARS-CoV-2 antibody, for COVID-19-related moderate pneumonia: a randomized, double-blind, placebo-controlled, phase IIa study 94%
- Enisamium reduces influenza virus shedding and improves patient recovery by inhibiting viral RNA polymerase activity 94%
Similar papers in this journal
- Early Treatment of Favipiravir in COVID-19 Patients Without Pneumonia: A Multicentre, Open-Labelled, Randomized Control Study 94%
- Validation and clinical evaluation of a SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT) 91%
- Replication Kinetics, Pathogenicity and Virus-induced Cellular Responses of Cattle-origin Influenza A(H5N1) Isolates from Texas, United States 89%
Similar papers in this journal
- Stenoparib, an inhibitor of cellular poly (ADP-ribose) polymerases (PARPs), blocks in vitro replication of SARS-CoV-2 variants 92%
- Phase I study on the pharmacokinetics of intravaginal, self-administered artesunate vaginal pessaries among women in Kenya 91%
- Effects of a rifampicin pre-treatment on linezolid pharmacokinetics 91%
Similar papers in this journal
- Innovative Randomized Phase 1 Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir 94%
- A dose-finding study to guide use of verapamil as an adjunctive therapy in tuberculosis 93%
- A user-driven framework for dose selection in pregnancy: proof-of-concept for sertraline 89%
Similar papers in this journal
- Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5’-triphosphate exposure to support posology for SARS-CoV-2 95%
- Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a phase 1, dose-escalating, randomised controlled study 91%
- Optimal dosing of cefotaxime and desacetylcefotaxime for critically ill paediatric patients. Can we use microsampling? 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.